Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Pena

Obstetrics Redding, CA Medical Doctor

NPI 1881799658 CMS profile 175849

2510 Airpark Dr, Suite 203, Redding, CA 96001

Open in the dashboard

General payments

$798

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jorge Pena of Redding, CA is reported in the CMS Open Payments database as having received $798 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 2
2023 General $62 3
2022 General $296 13
2021 General $118 6
2020 General $168 10
2019 General $112 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Pena
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Jorge Pena were reported at $43. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Jorge Pena Obstetrics median Middle half National median
2019 $112 $177 $60–$381 $163
2020 $168 $92 $35–$201 $114
2021 $118 $125 $40–$351 $132
2022 $296 $186 $65–$448 $149
2023 $62 $183 $61–$451 $160
2024 $0 $176 $62–$406 $164
2025 $43 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $228 12 payments
  2. TherapeuticsMD, Inc. $141 7 payments
  3. AbbVie, Inc. $90 5 payments
  4. Daiichi Sankyo Inc. $65 3 payments
  5. 180 Medical, Inc. $55 2 payments
  6. Ethicon US, LLC $43 2 payments
  7. Urovant Sciences Inc $28 1 payment
  8. Alydia Health $25 1 payment
  9. Boston Scientific Corporation $19 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $19 1 payment
  11. Other $85 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $762 38 payments
  2. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. PREMARIN $209 11 payments
  2. ESTRING $108 6 payments
  3. COLOGUARD $89 5 payments
  4. MYFEMBREE $84 4 payments
  5. ANNOVERA $70 3 payments
  6. INJECTAFER $65 3 payments
  7. NURTEC ODT $65 3 payments
  8. PAXLOVID $65 3 payments
  9. ORILISSA $59 3 payments
  10. GENTLECATH $55 2 payments
  11. Other $489 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

481

Median for Obstetrics & Gynecology: 65

Drug cost

$16,791

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

25.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 117 $12,284
Oxybutynin Chloride Generic 82 $1,341
Estradiol (Once Weekly) Estradiol Brand 15 $1,212
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 21 $647
Oxybutynin Chloride Er Oxybutynin Chloride Brand 28 $537
Cefdinir Generic 18 $184
Cephalexin Generic 52 $135
Ciprofloxacin Hcl Generic 44 $119
Amitriptyline Hcl Generic 13 $115
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 60 $113

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$84,604

Medicare's payments for the services billed

Medicare patients

359

Average age 74

Services billed

1,266

359 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 50%
Diabetes 29%
Osteoporosis 24%
Chronic kidney disease 20%
Depression 18%
Cancer 16%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record